Evidence map›Paper›PMID 42232153›Full record

ReviewJournal of inflammation research2026

The NLRP3-α-Synuclein Circuit: A Core Driver and Therapeutic Target in Parkinson's Disease.

Keting Liu, Zemin He, Lihao Zhang, Yong-Ming Wu, Li Xiao

Abstract readReview
In one paragraph

Review in Journal of inflammation research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

5 authors.

Keting LiuDepartment of Neurology, Chengdu Seventh People's Hospital, Affiliated Cancer Hospital of Chengdu Medical College, Chengdu, Sichuan, 610213, People's Republic of China.
Zemin HeDepartment of Thoracic Surgery, The First People's Hospital of Shuangliu District, Chendu, Sichuan Province, People's Republic of China.
Lihao ZhangDepartment of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, People's Republic of China.
Yong-Ming WuDepartment of Neurology, Nanfang Hospital, Southern Medical University, Guangzhou, Guangdong Province, 510515, People's Republic of China.
Li XiaoDepartment of Human Anatomy, Aging Mechanisms and Interventions Key Laboratory of Sichuan Province, Chengdu Medical College, Chengdu, Sichuan Province, 610500,People's Republic of China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The neuroinflammatory mechanisms underlying Parkinson's disease (PD) have evolved from a view of localized central events to a systemic network perspective involving "brain-periphery" interactions. The NLRP3 inflammasome, as a core component of the innate immune system, plays a pivotal role within this network. This review aims to systematically elucidate NLRP3's multifaceted roles in PD: First, it delves into the "self-amplifying" vicious cycle between α-synuclein pathology and NLRP3 activation, supports the hypothesis that this cycle may serve as a core engine. Second, it transcends central nervous system limitations to systematically examine how the central-peripheral immune interaction network-comprising gut microbiota and peripheral immune cells-regulates this cycle. Third, it objectively evaluates the potential and current limitations of NLRP3 pathway-associated molecules as biomarkers for disease diagnosis and progression monitoring. Fourth, it comprehensively reviews therapeutic strategies targeting NLRP3 and critically examines key challenges in their clinical translation. This paper provides an integrated perspective for understanding PD as a systemic inflammatory disease and offers a theoretical framework for future biomarker development and precision treatment strategies based on this pathway.

Indexed as

neuroinflammationNLRP3 inflammasomeParkinson’s diseasepyroptosistherapeutic targetsα-synuclein

Identifiers

PMID42232153
PMCPMC13225011

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.